Skip to content
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Neurology · Myotonic Dystrophy Type 1

What Is the Life Expectancy for Myotonic Dystrophy (DM1)?

At a Glance

Adult-onset myotonic dystrophy type 1 (DM1) historically lowers average life expectancy to around 58 years. However, because the primary threats to longevity are respiratory and cardiac complications, proactively managing your lung and heart health with modern interventions can profoundly improve your prognosis.

Receiving a diagnosis of adult-onset myotonic dystrophy type 1 (DM1) is undoubtedly overwhelming, and wondering how it will affect your lifespan is a completely normal, understandable reaction. To answer your question directly: yes, adult-onset DM1 does affect life expectancy, often shortening it compared to the general population [1]. Studies tracking large groups of people with adult-onset DM1 have found an average age of death around 58 years [1][2]. However, it is vital to understand that this number is a historical average, not a crystal ball for your individual future. Because we now know that the primary threats to longevity in DM1 are treatable breathing and heart complications [3][4], proactively managing your care with modern medical interventions can profoundly improve your prognosis.

Life Expectancy by Subtype

Myotonic dystrophy type 1 is caused by a genetic mutation—specifically, a CTG trinucleotide repeat expansion, which means a certain segment of DNA repeats more times than it should [5][6]. Generally, larger repeat numbers correlate with an earlier age of onset and a more severe impact on lifespan [5][7].

  • Late-Onset (Mild) DM1: This form usually appears later in life (often after age 50) and primarily involves mild muscle weakness or cataracts [8][9]. While it is considered the mildest form, it is not benign; individuals with late-onset DM1 are still at risk for life-threatening heart rhythm issues and require the exact same thorough screening as other subtypes [9][10].
  • Adult-Onset (Classic) DM1: This is the most common form, typically appearing in the teens or twenties. As mentioned, the average age of death in recent studies was 58 years [1], with mortality risks higher than the general population [11]. Progression is gradual, involving multiple body systems over decades [8].
  • Congenital DM1: The most severe form, present at birth. It carries a high risk of neonatal mortality (around 16%) due to severe breathing difficulties early on [12][13]. For those who survive infancy, the average age of death is roughly 46 years [2][13].

(Note: Many common symptoms, such as lower gastrointestinal issues, heavily impact daily quality of life but are not directly linked to a shortened lifespan [2]. However, swallowing difficulties—known as dysphagia—are a critical exception, as they can lead to dangerous, life-threatening pneumonia [14].)

The Primary Threats to Longevity

Unlike many other muscle diseases, mortality in DM1 is rarely caused by skeletal muscle weakness alone. The main drivers of premature mortality are specific complications in the lungs and heart [3][14].

Respiratory Complications

Breathing issues are a leading cause of mortality in DM1 [4][15]. This is driven by weakness in the respiratory muscles, leading to a restrictive ventilatory pattern—meaning the lungs cannot fully expand [16]. Over time, this muscle weakness causes:

  • Alveolar hypoventilation: Breathing that is too shallow or too slow to meet the body’s needs [16].
  • Chronic hypercapnia: A dangerous buildup of carbon dioxide in the blood because the lungs cannot exhale it efficiently [16]. Red flag symptoms of carbon dioxide buildup include frequent morning headaches, unrefreshing sleep, and excessive daytime sleepiness.
  • Sleep-disordered breathing: Including sleep apnea and inadequate oxygenation during sleep [16].

When breathing is chronically compromised, the risk of fatal respiratory tract infections and pneumonia significantly increases, especially if you have untreated swallowing difficulties [14].

Cardiac Complications

The second major threat to longevity is the heart. The genetic mutation associated with DM1 can damage the heart’s electrical system and muscle tissue, increasing the risk of sudden cardiac death (SCD) [7][17]. Heart-related risks include:

  • Conduction defects: Delays or blockages in the electrical signals that tell the heart to beat [7][18].
  • Arrhythmias: Irregular heartbeats, which can occur even if you have the “mild” late-onset form [9][7].
  • Left ventricular dysfunction: Weakness in the heart’s main pumping chamber [7][19].

Improving Your Prognosis with Proactive Care

The statistics around life expectancy in DM1 can be frightening, but they highlight exactly why proactive medical intervention is so powerful. Because we know how DM1 threatens longevity, you and your care team can take specific actions to protect yourself.

The very first step after diagnosis is to establish a baseline—you need comprehensive pulmonary and cardiac evaluations immediately to know where your lung and heart function currently stand [20]. From there, management by a specialized multidisciplinary team is highly recommended [20].

Protecting Your Lungs

A cornerstone of extending life with DM1 is the use of Non-Invasive Ventilation (NIV), such as a BiPAP machine [15][3]. NIV supports your breathing muscles while you sleep, preventing the dangerous buildup of carbon dioxide and reducing the strain on your body.

  • Consistently using prescribed home ventilation is directly associated with a reduced risk of mortality [15].
  • Conversely, failure to adhere to prescribed NIV significantly increases mortality risk [15][4].
  • Additionally, undergo regular swallowing evaluations with a speech-language pathologist. Modifying your diet or learning safe swallowing techniques can prevent fatal aspiration pneumonia [14].

Protecting Your Heart

Because cardiac involvement is so prevalent and life-threatening, regular, lifelong monitoring is absolutely essential for all DM1 patients [21][22].

  • Standard care includes an annual ECG (electrocardiogram), 24-hour Holter monitoring (a wearable device that tracks your heart rhythm for a full day), and echocardiograms (ultrasound of the heart) [21][22].
  • Twenty-four-hour Holter monitors are crucial because they can detect dangerous arrhythmias that a standard, brief ECG might miss [22].
  • Identifying abnormal electrical patterns early allows cardiologists to intervene proactively—often by implanting a pacemaker or an implantable cardioverter-defibrillator (ICD)—to prevent sudden cardiac death [18][19].

A Critical Warning on Anesthesia and Medications

People with DM1 have severe, potentially life-threatening reactions to general anesthesia and respiratory depressants (such as opioids, certain sleep aids, and muscle relaxants) [4]. These medications can dangerously suppress your already weakened breathing system. Always inform your anesthesiologist, surgeon, and dentist about your DM1 diagnosis prior to any procedure, even minor ones.

(Finally, while not the primary driver of mortality, DM1 carries an increased risk for certain cancers. Staying up-to-date on routine, age-appropriate cancer screenings adds another layer of protection to your long-term health.)

By staying fiercely proactive about your breathing, swallowing, and heart health, you give yourself the best possible chance to maximize both the length and quality of your life with adult-onset DM1.

Common questions in this guide

Does myotonic dystrophy type 1 shorten your lifespan?
Yes, adult-onset DM1 generally shortens life expectancy compared to the general population, with historical studies showing an average lifespan of about 58 years. However, by proactively treating heart and lung complications, you can significantly improve your prognosis and extend your life.
What is the most common cause of death in myotonic dystrophy type 1?
Unlike many other muscle diseases, mortality in DM1 is rarely caused by muscle weakness alone. The leading causes of premature death are breathing issues, such as pneumonia and respiratory failure, and cardiac complications like sudden cardiac death.
How does the CTG repeat number affect my prognosis?
Myotonic dystrophy type 1 is caused by a repeating segment of DNA called a CTG repeat expansion. In general, a larger number of these genetic repeats is linked to an earlier onset of symptoms and a more severe impact on lifespan.
What are the signs of carbon dioxide buildup in DM1?
Weakened breathing muscles can cause carbon dioxide to dangerously build up in your blood while you sleep. Warning signs of this include frequent morning headaches, waking up feeling unrefreshed, and excessive daytime sleepiness.
Why is general anesthesia dangerous for people with DM1?
People with DM1 can have severe, life-threatening reactions to general anesthesia and respiratory depressants because these medications further weaken an already compromised breathing system. You must always alert your doctors, surgeons, and dentists about your DM1 diagnosis before any procedure.

Questions for Your Doctor

5 questions

  • What was the exact size of my CTG repeat expansion, and what does that number tell us about my specific disease progression risks?
  • Can you refer me to a specialized neuro-cardiologist and pulmonologist to establish my baseline heart and lung evaluations immediately?
  • How frequently should I be scheduled for full pulmonary function tests, and at what point will we consider a sleep study to check for nighttime breathing issues?
  • Who on my care team will be acting as the "quarterback" to ensure my multidisciplinary heart, lung, and swallowing monitoring is never delayed?
  • How can we ensure my medical chart prominently flags my severe risks regarding general anesthesia and respiratory depressant medications?

Questions for You

4 questions

  • Am I experiencing any morning headaches, excessive daytime sleepiness, or unrefreshing sleep that might indicate carbon dioxide buildup overnight?
  • Do I ever feel my heart fluttering, racing, or skipping beats out of nowhere?
  • Have I noticed myself coughing while drinking water or clearing my throat often while eating, which could indicate a swallowing issue?
  • Have I established a reliable system or calendar routine to ensure I never miss my annual cardiac and respiratory screenings?

References

References (22)
  1. 1

    Multiorgan Involvement and Mortality in Individuals With Adult-Onset Myotonic Dystrophy (DM1)-A Danish Register-Based Study I.

    Werlauff U, Rudolfsen JH, Andersen H, et al.

    European journal of neurology 2025; (32(4)):e70135 doi:10.1111/ene.70135.

    PMID: 40195688
  2. 2

    Survival in myotonic dystrophy type 1: a long time follow up-study with special reference to gastrointestinal symptoms.

    Rönnblom A, Ekbom A

    Upsala journal of medical sciences 2024; (129()) doi:10.48101/ujms.v129.10663.

    PMID: 39376588
  3. 3

    Update on the clinical and therapeutic aspects of myotonic dystrophy type 1.

    Takahashi MP

    Current opinion in neurology 2025; (38(5)):531-537 doi:10.1097/WCO.0000000000001374.

    PMID: 40377703
  4. 4

    Cardiac Involvement and Arrhythmias Associated with Myotonic Dystrophy.

    McBride D, Deshmukh A, Shore S, et al.

    Reviews in cardiovascular medicine 2022; (23(4)) doi:10.31083/j.rcm2304126.

    PMID: 36177340
  5. 5

    The Study of the Inheritance Mechanisms of Myotonic Dystrophy Type 1 (DM1) in Families from the Republic of North Ossetia-Alania.

    Ionova SA, Murtazina AF, Marakhonov AA, et al.

    International journal of molecular sciences 2024; (25(17)) doi:10.3390/ijms25179734.

    PMID: 39273681
  6. 6

    Myotonic dystrophy type 1 testing, 2024 revision: A technical standard of the American College of Medical Genetics and Genomics (ACMG).

    Seifert BA, Reddi HV, Kang BE, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2024; (26(8)):101145 doi:10.1016/j.gim.2024.101145.

    PMID: 38836869
  7. 7

    Association Between Mutation Size and Cardiac Involvement in Myotonic Dystrophy Type 1: An Analysis of the DM1-Heart Registry.

    Chong-Nguyen C, Wahbi K, Algalarrondo V, et al.

    Circulation. Cardiovascular genetics 2017; (10(3)) doi:10.1161/CIRCGENETICS.116.001526.

    PMID: 28611030
  8. 8

    Myotonic dystrophy type 1: A comparison between the adult- and late-onset subtype.

    Joosten IBT, Horlings CGC, Vosse BAH, et al.

    Muscle & nerve 2023; (67(2)):130-137 doi:10.1002/mus.27766.

    PMID: 36484161
  9. 9

    Myotonic Dystrophy.

    Perez PG

    Continuum (Minneapolis, Minn.) 2025; (31(5)):1437-1461 doi:10.1212/cont.0000000000001621.

    PMID: 41037177
  10. 10

    A 9-year follow-up study of quantitative muscle strength changes in myotonic dystrophy type 1.

    Gagnon C, Petitclerc É, Kierkegaard M, et al.

    Journal of neurology 2018; (265(7)):1698-1705 doi:10.1007/s00415-018-8898-4.

    PMID: 29785524
  11. 11

    [Adult myotonic dystrophy type 1: an update].

    Rosado-Bartolomé A, Gutiérrez-Gutiérrez G, Prieto-Matos J

    Semergen 2020; (46(5)):355-362 doi:10.1016/j.semerg.2020.01.002.

    PMID: 32646725
  12. 12

    Corpus Callosum Diffusion Restriction in Neonatal Congenital Myotonic Dystrophy.

    Sakatani N, Ikeda H, Inami Y, et al.

    Cureus 2025; (17(10)):e94776 doi:10.7759/cureus.94776.

    PMID: 41250692
  13. 13

    Prenatal, Neonatal, and Early Childhood Features in Congenital Myotonic Dystrophy.

    Zapata-Aldana E, Ceballos-Sáenz D, Hicks R, Campbell C

    Journal of neuromuscular diseases 2018; (5(3)):331-340 doi:10.3233/JND-170277.

    PMID: 30010141
  14. 14

    [Medical emergency card for Steinert's disease: an unmet need].

    Rosado-Bartolomé A, Domínguez-González C

    Revista de neurologia 2023; (76(1)):15-19 doi:10.33588/rn.7601.2022380.

    PMID: 36544372
  15. 15

    Effect and impact of mechanical ventilation in myotonic dystrophy type 1: a prospective cohort study.

    Boussaïd G, Prigent H, Laforet P, et al.

    Thorax 2018; (73(11)):1075-1078 doi:10.1136/thoraxjnl-2017-210610.

    PMID: 29572271
  16. 16

    Respiratory dysfunction in myotonic dystrophy type 1: A systematic review.

    Hawkins AM, Hawkins CL, Abdul Razak K, et al.

    Neuromuscular disorders : NMD 2019; (29(3)):198-212 doi:10.1016/j.nmd.2018.12.002.

    PMID: 30765255
  17. 17

    Two Mutations in Thyroid Hormone Receptor Beta Gene (P453A and C36Y) in a Family with Resistance to Thyroid Hormone with Comorbid Myotonic Dystrophy.

    Takeda K, Nemoto KI, Hayashi Y, et al.

    Thyroid : official journal of the American Thyroid Association 2019; (29(4)):607-608 doi:10.1089/thy.2018.0307.

    PMID: 30672388
  18. 18

    Electrocardiographic predictors of infrahissian conduction disturbances in myotonic dystrophy type 1.

    Joosten IBT, van Lohuizen R, den Uijl DW, et al.

    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2021; (23(2)):298-304 doi:10.1093/europace/euaa256.

    PMID: 33150426
  19. 19

    Cardiac Pathology in Myotonic Dystrophy Type 1.

    Mahadevan MS, Yadava RS, Mandal M

    International journal of molecular sciences 2021; (22(21)) doi:10.3390/ijms222111874.

    PMID: 34769305
  20. 20

    Comprehensive Cardiovascular Management of Myotonic Dystrophy Type 1 Patients: A Report from the Italian Neuro-Cardiology Network.

    Russo V, Antonini G, Massa R, et al.

    Journal of cardiovascular development and disease 2024; (11(2)) doi:10.3390/jcdd11020063.

    PMID: 38392277
  21. 21

    Natural history of cardiac involvement in myotonic dystrophy type 1 - Emphasis on the need for lifelong follow-up.

    Petri H, Mohammad BJY, Kristensen AT, et al.

    International journal of cardiology 2024; (406()):132070 doi:10.1016/j.ijcard.2024.132070.

    PMID: 38643802
  22. 22

    An evaluation of 24 h Holter monitoring in patients with myotonic dystrophy type 1.

    Joosten IBT, Janssen CEW, Horlings CGC, et al.

    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2023; (25(1)):156-163 doi:10.1093/europace/euac104.

    PMID: 35851806

This page provides information on myotonic dystrophy type 1 life expectancy for educational purposes. Always consult your neurologist, cardiologist, and pulmonologist for personalized guidance regarding your specific prognosis and treatment plan.

Get notified when new evidence is published on Steinert myotonic dystrophy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.